Russian clinical recommendations on diagnosis and management of diffuse B-large cell lymphoma (version 2012).

CLINICAL GUIDELINES

Tumyan G.S., Osmanov Ye.A., Kravchenko S.K., Mikhaylova N.B., Pospelova T.I., Konstantinova T.S., Baykov V.V., Kovrigina A.M., Krivolapov YU.A., Kokosadze N.V., Tupitsyn N.N., Sotnikov V.M., Trofimova O.P., Stefanov D.N., Pfreundschuh M., Poddubnaya I.V.

Read in PDF (RUS)pdficon

References

  1. Harris N.L., Jaffe E.S., Diebold J. et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol. 1999; 17(12): 3835–49.
  2. Swerdlow S.H., Campo E., Harris N.L. et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2008.
  3. Hans C.P., Weisenburger D.D., Greiner T.C. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103(1): 275–82.
  4. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N. Engl. J. Med. 1993; 329(14): 987–94.
  5. Kridel R., Dietrich P.Y. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol. 2011; 12: 1258–66.
  6. Pfreundschuh M., Trumper L., Osterborg A. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379–91.
  7. Miller T.P., Dahlberg S., Cassady J.R. et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med. 1998; 339(1): 21–6.
  8. Shenkier T.N., Voss N., Fairey R. et al. Brief chemotherapy and involvedregion irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J. Clin. Oncol. 2002; 20(1): 197–204.
  9. Horning S.J., Weller E., Kim K. et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J. Clin. Oncol. 2004; 22(15): 3032–8.
  10. Bonnet C., Fillet G., Mounier N. et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol. 2007; 25(7): 787–92.
  11. Phan J., Mazloom A., Medeiros L.J. et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J. Clin. Oncol. 2010; 28(27): 4170–6.
  12. Румянцев А.Г., Птушкин В.В., Семочкин С.В. Пути улучшения результатов лечения злокачественных опухолей у подростков и молодых взрослых. Онкогематология 2011; 1: 20–30. Rumyantsev A.G., Ptushkin V.V., Semochkin S.V. Puti uluchsheniya rezultatov lecheniya zlokachestvennykh opukholey u podrostkov i molodykh vzroslykh [Approaches to improvement of treatment outcomes in adolescents and young adults with malignancies. In: Oncohematology]. Onkogematologiya 2011; 1: 20–30.
  13. Reiter A., Schrappe M., Tiemann M. et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-M nster Group Trial NHL-BFM 90. Blood. 1999; 94(10): 3294–306.
  14. Бобкова М.М., Семочкин С.В., Иванова В.Л. и др. Эффективность применения интенсивной полихимиотерапии в лечении молодых больных с диффузной В-крупноклеточной лимфомой из клеток герминального центра. Онкогематология 2009; 4: 4–11. [Bobkova M.M., Semochkin S.V., Ivanova V.L. i dr. Effektivnost primeneniya intensivnoy polikhimioterapii v lechenii molodykh bolnykh s diffuznoy V-krupnokletochnoy limfomoy iz kletok germinalnogo tsentra (Efficacy of intensive polychemotherapy in young patients with diffuse large B-cell lymphoma from germinal center. In: Oncohematology). Onkogematologiya 2009; 4: 4–11.]
  15. Wilson W.H., Dunleavy K., Pittaluga S. et al. Phase II study of doseadjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J. Clin. Oncol. 2008; 26(16): 2717–24.
  16. Coiffier B., Lepage E., Briere J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346: 235–42.
  17. Peyrade F., Jardin F., Thieblemont C. et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011; 12: 460–8.
  18. Chao N.J., Rosenberg S.A., Horning S.J. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin’s lymphoma. Blood 1990; 76(7): 1293–8.
  19. Moccia A.A., Schaff K., Hoskins P. et al. R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 408.
  20. Philip T., Guglielmi C., Hagenbeek A. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N. Engl. J. Med. 1995; 333(23): 1540–5.
  21. Velasquez W.S., Cabanillas F., Salvador P. et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71(1): 117–22.
  22. Velasquez W.S., McLaughlin P., Tucker S. et al. ESHAP — an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year followup study. J. Clin. Oncol. 1994; 12(6): 1169–76.
  23. Crump M., Baetz T., Couban S. et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell nonHodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101(8): 1835–42.
  24. Kuruvilla J., Nagy T., Pintilie M. et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006; 106(2): 353–60.
  25. Zelenetz A.D., Hamlin P., Kewalramani T. et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann. Oncol. 2003; 14(Suppl. 1): i5–10.
  26. Coiffier B., Haioun C., Ketterer N. et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92(6): 1927–32.
  27. Мангасарова Я.К., Магомедова А.У., Кравченко С.К. и др. Диффузная В-крупноклеточная лимфома с первичным вовлечением лимфоузлов сре- достения: диагностика и лечение. Тер. арх. 2010; 7: 61–5. [Mangasarova Ya.K., Magomedova A.U., Kravchenko S.K. i dr. Diffuznaya V-krupnokletochnaya limfoma s pervichnym vovlecheniyem limfouzlov sredosteniya: diagnostika i lecheniye (Diffuse large B-cell lymphoma with primary involvement of mediastinal lymph nodes: diagnosis and treatment. In: Ther. archive). Ter. arkh. 2010; 7: 61–5.]
  28. Кичигина М.Ю., Тумян Г.С., Ковригина А.М. и др. Первичная медиа- стинальная (тимическая) В-крупноклеточная лимфома: обзор литературы и собственные данные. Тер. арх. 2011; 83(7): 38–46. [Kichigina M.Yu., Tumyan G.S., Kovrigina A.M. i dr. Pervichnaya mediastinalnaya (timicheskaya) V-krupnokletochnaya limfoma: obzor literatury i sobstvennye dannye (Primary mediastinal (thymic) large B-cell lymphoma: literature review and our own findings. In: Ther. archive). Ter. arkh. 2011; 83(7): 38–46.]
  29. Savage K.J., Al-Rajhi N., Voss N. et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann. Oncol. 2006; 17(1): 123–30.
  30. Zinzani P.L., Stefoni V., Finolezzi E. et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin. Lymph. Myel. 2009; 9(5): 381–5.
  31. Rieger M., Osterborg A., Pettengell R. et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann. Oncol. 2011; 22(3): 664–70.
  32. Vassilakopoulos T.P., Angelopoulou M.K., Galani Z. et al. RituximabCHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL). Blood (ASH Annual Meeting Abstracts) 2006; 108: Abstract 2745.
  33. Dunleavy K., Pittaluga S., Janik J. et al. Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients. Blood (ASH Annual Meeting Abstracts). 2006; 108: Abstract 209.
  34. Тумян Г.С., Сорокин Е.Н., Ковригина А.М. и др. Диффузная В-крупноклеточная лимфома с первичной локализацией в яичке. Клини- ческая онкогематология. Фунд. исслед. и клин. практ. 2008; 1(3): 206–10. [Tumyan G.S., Sorokin Ye.N., Kovrigina A.M. i dr. Diffuznaya V-krupnokletochnaya limfoma s pervichnoy lokalizatsiyey v yaichke (Diffuse large B-cell lymphoma with primary testicular involvement. In: Clinical hematology. Fund. stud. & clin. pract.). Klinicheskaya onkogematologiya. Fund. issled. i klin. prakt. 2008; 1(3): 206–10.]
  35. Сотникова О.П., Сорокин Е.Н., Поддубная И.В. Первичные неход- жкинские лимфомы яичка. Онкоурология 2012; 1: 88–94. [Sotnikova O.P., Sorokin Ye.N., Poddubnaya I.V. Pervichnye nekhodzhkinskiye limfomy yaichka (Primary non-Hodgkin’s testicular lymphomas. In: Oncourology). Onkourologiya 2012; 1: 88–94.]
  36. Gundrum J.D., Mathiason M.A., Moore D.B., Go R.S. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J. Clin. Oncol. 2009; 27(31): 5227.
  37. Mazloom A., Fowler N., Medeiros L.J., Iyengar P. et al. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M.D. Anderson Cancer Center experience. Leuk. Lymphoma 2010; 51(7): 1217–24.
  38. Vitolo U., Ferreri A.J., Zucca E. Primary testicular lymphoma. Crit. Rev. Oncol. Hematol. 2008; 65(2): 183–9.
  39. Hasselblom S., Ridell B., Wedel H. et al. Testicular lymphoma e a retrospective, population-based, clinical and immunohistochemical study. Acta Oncol. 2004; 43(8): 758–65.
  40. Пересторонина Т.Н., Кравченко С.К., Губкин А.В. и др. Первичная диффузная В-крупноклеточная лимфосаркома яичка с вовлечением центральной нервной системы. Гематол. и трансфузиол. 2009; 54(3): 25–7. [Perestoronina T.N., Kravchenko S.K., Gubkin A.V. i dr. Pervichnaya diffuznaya V-krupnokletochnaya limfosarkoma yaichka s vovlecheniyem tsentralnoy nervnoy sistemy (Primary diffuse large B-cell testicular lymphosarcoma with involvement of central nervous system. In: Hematol. & transfusiol.). Gematol. i transfuziol. 2009; 54(3): 25–7.]
  41. Vitolo U., Chiappella A., Ferreri A.J. et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J. Clin. Oncol. 2011; 29(20): 2766–72.
  42. Ahmad S.S., Idris S.F., Follows G.A., Williams M.V. Primary Testicular Lymphoma. Clin. Oncol. (R. Coll. Radiol). 2012; 24(5): 358–65.